{
    "clinical_study": {
        "@rank": "117940", 
        "arm_group": {
            "arm_group_label": "1", 
            "arm_group_type": "Experimental", 
            "description": "Weekly paclitaxel (50 mg/m2 IV) and weekly vinorelbine (20 mg/m2 IV) with daily G-CSF support and Herceptin for patients with HER-2/neu positive disease.  Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment."
        }, 
        "brief_summary": {
            "textblock": "The purposes of this are:\n\n        -  To determine the highest doses of Taxol and Navelbine that we can safely give to\n           patients;\n\n        -  To determine what kind of side effects are caused by the combination of Taxol,\n           Navelbine and G-CSF;\n\n        -  To determine whether the combination of Taxol, Navelbine and G-CSF is more effective\n           than standard therapy in treating metastatic breast cancer and prolonging life;"
        }, 
        "brief_title": "Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial", 
        "completion_date": {
            "#text": "August 2008", 
            "@type": "Actual"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION\n\n        To be eligible, volunteers must:\n\n          -  Have stage IV carcinoma of the breast that has been microscopically confirmed\n\n          -  Be age > 18\n\n          -  Be fully active or ambulatory with symptoms but able to do light work\n\n          -  Have a life expectancy of > 16 weeks\n\n          -  Be > 2 weeks from prior surgery; > 3 weeks from radiation therapy to the pelvis,\n             spine or long bones; > 3 weeks from prior chemotherapy (> 6 weeks for mitomycin C or\n             nitrosureas) and > 2 weeks from prior hormonal therapy\n\n          -  Have had one or less prior regimens for metastatic disease\n\n          -  Have measurable (bidimensionally) or evaluable disease that is in an area that has\n             not been radiated\n\n        EXCLUSION\n\n        Patients are not eligible if they:\n\n          -  Have rapidly progressing liver or lung metastases or uncontrolled central nervous\n             system metastases\n\n          -  Are medically unstable\n\n          -  Are pregnant, nursing or unwilling to employ adequate contraception\n\n          -  Have pre-existing clinically significant peripheral neuropathy except for\n             abnormalities due to cancer\n\n          -  Have psychological, familial, sociological or geographical conditions that do not\n             permit weekly medical follow-up and compliance with the study protocol\n\n          -  Have hypersensitivity to E. Coli-derived proteins, Filgrastim, or any of its\n             components\n\n          -  Have had prior therapy with Navelbine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 9, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00041470", 
            "org_study_id": "00-5891"
        }, 
        "intervention": [
            {
                "arm_group_label": "1", 
                "description": "50 mg/m2 IV weekly.  Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "1", 
                "description": "20 mg/m2 IV weekly.  Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.", 
                "intervention_name": "Vinorelbine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "1", 
                "description": "4 mg/kg IV loading dose day 1 of first week followed by 2 mg/kg IV maintenance dose  on each subsequent week.  Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.", 
                "intervention_name": "Trastuzumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "1", 
                "description": "5 mcg/kg daily including the day of IV chemotherapy. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.", 
                "intervention_name": "Filgrastim", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vinorelbine", 
                "Paclitaxel", 
                "Trastuzumab", 
                "Lenograstim"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 13, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98109-1023"
                }, 
                "name": "Seattle Cancer Care Alliance"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial", 
        "overall_official": {
            "affiliation": "University of Washington", 
            "last_name": "Julie R. Gralow, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "To measure the qualitative and quantitative toxicity of this regimen.", 
                "safety_issue": "Yes", 
                "time_frame": "<= 18 months"
            }, 
            {
                "measure": "To measure response rates, time to progression and survival in patients so treated.", 
                "safety_issue": "No", 
                "time_frame": "<= 4 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00041470"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Washington", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Amgen", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Bristol-Myers Squibb", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "GlaxoSmithKline", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Washington", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2001", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }, 
    "geocoordinates": {
        "Seattle Cancer Care Alliance": "47.606 -122.332"
    }
}